PUMA
3.3.2023 14:17:35 CET | Business Wire | Press release
Sports company PUMA kicked off the 2023 Formula 1 season with a special panel discussion to celebrate its legacy in Motorsport culture and discuss the importance of innovations in racewear production. It was the first of a series of events to mark PUMA’s 75th anniversary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230303005219/en/
Panel Talk ahead of the 2023 Formula 1 season to celebrate PUMAs legacy in Motorsport culture. (Photo: Business Wire)
Founded in 1948, PUMA has been at the forefront of innovation throughout its history, pushing the boundaries of what is possible in performance, functionality, and design. PUMA's rich history in motorsport dates back to 2001, when JORDAN GRAND PRIX became the first Formula 1 racing team that PUMA supplied with both footwear and clothing. Since then, PUMA has collaborated with some of the biggest names in the sport, including Michael Schumacher and Lewis Hamilton, and produced the best product for the best teams like Mercedes-AMG Petronas F1, Scuderia Ferrari and Red Bull Racing.
The panel talk was held in Bahrain on March 1 and was moderated by Noemi de Miguel, a sports journalist and television presenter for DAZN together with experts — Thomas Josnik (Global Director Motorsport, PUMA), Mick Schumacher (Mercedes-AMG Petronas F1 Team Reserve driver), Gregor Huebner (Senior Manager Sports Marketing Motorsport, PUMA) and Maurizio Sicco (Consultant in Motorsport racewear, PUMA) — they explored PUMA’s milestones in motorsport, discussed racing products from different eras, and spoke about what motorsport represents today.
PUMA’s latest racing shoes, SPEEDCAT PRO, were designed based on functionality to support drivers in their high performance on track. Years of innovation and technology packed into a single shoe, the SPEEDCAT PRO uses state of the art materials for racing. The upper and lining are made of lightweight fabric for speed, comfort, and of course fire protection. To guarantee absolute control of the pedals, the SPEEDCAT PRO comes with a low-profile rubber outsole and an EVA wedge provides just the right amount of comfort while keeping the shoe light and nimble. The SPEEDCAT PRO was built in compliance with the latest FIA Homologation Regulations for Safety Equipment (FIA Standard 8856-2018) for the best protection in racing. The SPEEDCAT PRO also includes several design elements that pay homage to PUMA's racing heritage.
“PUMA is proud to celebrate its 75th anniversary this year and also our legacy in motorsport industry”, said Thomas Josnik Global Director Motorsport at PUMA. “Innovation, speed, and technology have always been at the heart of everything we do, and this event is a tribute to our commitment to pushing boundaries and driving change in the industry.”
The event was an exciting first step in this year of celebration of 75 years of PUMA's past, present, and future in motorsport, highlighting the brand's commitment to excellence and innovation in racewear.
Event recap (YouTube): HERE
Event pictures: HERE
PUMA 75 Lewis Hamilton Interview: HERE
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling, and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 18,300 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005219/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom